US Patent 11,951,111: Lybalvi Bilayer Tablet Claims, Exclusivity and Generic-Entry Risk
US Patent 11,951,111 protects methods of treating schizophrenia or bipolar I disorder with once-daily, immediate-release bilayer tablets containing olanzapine and 10 mg samidorphan. The patent is directed to the commercial dosage-form architecture associated with Lybalvi, including separate olanzapine and samidorphan layers, specified excipient ranges, rapid dissolution, tablet stability, and selected olanzapine strengths.
The principal commercial risk is formulation-specific rather than molecule-wide. A generic olanzapine product, or a product containing samidorphan in a different dosage form, would not necessarily infringe. An ANDA product that reproduces the covered bilayer composition, dissolution profile, dosage regimen and treatment indication would face substantially greater risk.
What does US Patent 11,951,111 protect?
The patent contains method-of-treatment claims requiring administration of a coated immediate-release bilayer tablet. The claims combine four main limitations:
- A patient with schizophrenia or bipolar I disorder.
- Once-daily oral administration.
- A fixed-dose combination of olanzapine and 10 mg samidorphan.
- A bilayer tablet with defined formulation and dissolution characteristics.
The claims do not broadly cover every olanzapine-samidorphan combination. They require a particular tablet design and, in most claims, specific excipient ranges.
| Claim group |
Principal protected subject matter |
Olanzapine strengths |
Key dissolution requirement |
| Claims 1-9 |
Bilayer tablet with specified excipient ranges, magnesium stearate and rapid release |
5, 10, 15, 20 mg |
At least 97% of each active after 30 minutes at pH 1.0 |
| Claim 2 |
Claim 1 formulation with an additional pH 4.5 dissolution limitation |
5, 10, 15, 20 mg |
At least 97% of each active after 30 minutes at pH 4.5 |
| Claim 3 |
Samidorphan L-malate at 13.6 mg, equivalent to 10 mg samidorphan |
5, 10, 15, 20 mg |
Inherits claim 1 |
| Claim 4 |
Stability limitation for olanzapine degradation impurities |
5, 10, 15, 20 mg |
Less than 0.5 wt% impurities after six months |
| Claim 5 |
Crospovidone in both layers |
5, 10, 15, 20 mg |
Inherits claim 1 |
| Claims 6-9 |
Individual olanzapine strengths |
5, 10, 15, 20 mg |
Inherit claim 1 |
| Claims 10-11 |
Narrow formulation using 13.6 mg samidorphan L-malate and approximately 40% microcrystalline cellulose in both layers |
5, 10, 15, 20 mg |
At least 97% after 30 minutes at pH 1.0 |
| Claim 12 |
Broader bilayer formulation with a 15-minute dissolution test |
5, 10, 15, 20 mg |
At least 85% of each active after 15 minutes at pH 4.5 |
| Claim 13 |
Broadest formulation range, including 2.5 mg olanzapine |
2.5, 5, 10, 15, 20 mg |
At least 97% after 30 minutes at pH 1.0 |
How do the independent claims differ?
Claims 1, 10, 12 and 13 are independent method claims. Their practical breadth differs materially.
Claim 1
Claim 1 requires:
- 10 mg samidorphan, or a salt providing that amount;
- a first samidorphan layer with approximately 35% to 43% microcrystalline cellulose;
- approximately 37% to 43% lactose or lactose hydrate;
- 1.5% to 2% magnesium stearate;
- a second olanzapine layer with 5 mg, 10 mg, 15 mg or 20 mg olanzapine;
- approximately 38% to 42% microcrystalline cellulose;
- approximately 46% to 49% lactose or lactose hydrate;
- approximately 1% magnesium stearate;
- a film coating; and
- at least 97% release of both active ingredients after 30 minutes at pH 1.0.
The claim requires the claimed excipients in each layer, but it does not expressly exclude additional excipients. A competing product could therefore attempt to avoid infringement by changing the composition outside the recited ranges, altering the bilayer structure, or failing the specified dissolution test.
Claim 10
Claim 10 is narrower in composition but potentially stronger as an infringement target because it identifies the commercial salt and more exact formulation values:
- 13.6 mg samidorphan L-malate;
- approximately 40% microcrystalline cellulose in the samidorphan layer;
- approximately 42% lactose monohydrate;
- approximately 1.75% magnesium stearate;
- approximately 40% microcrystalline cellulose in the olanzapine layer;
- approximately 47% lactose or lactose hydrate; and
- approximately 1% magnesium stearate.
Claim 11 adds particle-size ranges for samidorphan L-malate:
| Particle-size parameter |
Claimed range |
| D10 |
Approximately 10-80 micrometers |
| D50 |
Approximately 40-200 micrometers |
| D90 |
Approximately 100-300 micrometers |
This limitation gives a generic applicant an additional design-around route, but it also creates a fact-intensive infringement question. Particle-size distributions can vary with sampling, milling, analytical method and batch.
Claim 12
Claim 12 omits the explicit magnesium stearate limitations found in claim 1 and uses broader excipient ranges:
- 30% to 45% microcrystalline cellulose in the samidorphan layer;
- 35% to 50% lactose or lactose hydrate in that layer;
- 35% to 45% microcrystalline cellulose in the olanzapine layer; and
- 45% to 55% lactose or lactose hydrate in that layer.
Its dissolution threshold is also less demanding: at least 85% release of each active after 15 minutes at pH 4.5. This claim is broader in formulation scope than claim 1, although its infringement analysis still depends on the full claim combination.
Claim 13
Claim 13 has the broadest stated olanzapine dose range because it includes 2.5 mg. It also uses broad excipient ranges and omits magnesium stearate as an express limitation.
The claim requires at least 97% release of both actives after 30 minutes at pH 1.0. It may therefore capture formulations outside the narrower commercial composition claims if they remain within the stated excipient ranges and meet the dissolution requirement.
What formulation and manufacturing elements are protected?
The patent’s formulation protection centers on physical separation of the two active ingredients into a bilayer tablet. The claim structure indicates that the inventors were addressing compatibility, stability and dissolution issues associated with combining olanzapine and samidorphan.
The protected elements include:
- separate samidorphan and olanzapine tablet layers;
- a coated immediate-release dosage form;
- microcrystalline cellulose as a major filler in both layers;
- lactose or lactose hydrate as a second major filler;
- magnesium stearate within specified ranges in key claims;
- crospovidone in dependent claim 5;
- samidorphan L-malate in claims 3 and 10-11;
- particle-size distribution of samidorphan L-malate;
- rapid dissolution at pH 1.0 or pH 4.5; and
- stability against olanzapine degradation impurities.
The claims do not expressly cover the manufacturing process itself. They do not require a particular granulation method, compression force, blending order, coating process or equipment configuration. A manufacturing process could still create infringement risk if it produces a tablet meeting all method-claim limitations.
What is the FDA and Orange Book status of the patent?
Lybalvi, the commercial olanzapine/samidorphan product, was approved by FDA on June 1, 2021, under NDA 214378 for adults with schizophrenia and bipolar I disorder. The approved strengths are 5 mg/10 mg, 10 mg/10 mg, 15 mg/10 mg and 20 mg/10 mg olanzapine/samidorphan combinations. [1]
US Patent 11,951,111 is directed to the same therapeutic combination and dosage-form platform. Orange Book relevance depends on whether the patent is listed against the approved NDA and whether the listed claims read on the approved product. FDA Orange Book listings are the operative source for determining whether an ANDA applicant must make a patent certification for this patent. [2]
The regulatory exclusivity framework is separate from patent exclusivity:
| Protection |
Relevant timing |
| FDA approval |
June 1, 2021 |
| Five-year new chemical entity exclusivity |
Nominally through June 1, 2026 |
| ANDA Paragraph IV filing eligibility |
Generally available after four years, subject to statutory exceptions |
| Patent protection |
Depends on the continuation family’s earliest effective nonprovisional filing date, patent-term adjustment and any terminal disclaimer |
| Pediatric exclusivity |
Six additional months only if FDA grants qualifying pediatric exclusivity |
The NCE exclusivity period does not prevent an ANDA filing before its expiration if the applicant uses a permitted pathway, but it generally prevents FDA approval of a standard ANDA during the protected period. Patent-listed claims can continue to block approval after regulatory exclusivity expires.
When does US Patent 11,951,111 expire?
The patent’s expiration date must be determined from the complete continuation-family record, including the earliest effective nonprovisional filing date, patent-term adjustment and any terminal disclaimer. The patent number and claim text alone do not establish the final enforceable expiration date.
Because US 11,951,111 is a formulation patent granted in a continuation family, the relevant date is not the 2024 grant date. The term normally runs 20 years from the earliest effective nonprovisional filing date in the priority chain, subject to adjustments under 35 U.S.C. §§ 154 and 156.
The commercial assessment should therefore use the USPTO Patent Center term calculation and the current Orange Book listing rather than the issue date. A patent continuing from the Lybalvi formulation family can extend materially beyond the 2026 FDA exclusivity date.
Which companies are likely to challenge Lybalvi exclusivity?
Potential challengers are manufacturers with existing CNS generic infrastructure, including companies active in generic olanzapine, antipsychotic tablets or complex oral fixed-dose combinations. Public identification of a specific Paragraph IV challenger requires an ANDA notice letter or litigation filing.
The relevant challenge paths are:
- Paragraph IV certification that a listed patent is invalid, unenforceable or not infringed.
- Paragraph III certification with a proposed launch after patent expiration.
- Section viii carve-out of a patented method of use, where the applicant can remove the protected indication from its labeling.
- Formulation design-around using different excipient ranges, dissolution characteristics or tablet architecture.
A Section viii strategy is difficult against claims that are framed as formulation-dependent treatment methods and cover the approved schizophrenia and bipolar I indications. A successful carve-out would need to remove the patented use without undermining the remaining FDA-approved labeling.
What litigation and settlement risks affect generic launch?
A Paragraph IV notice for an Orange Book-listed patent can trigger a 45-day period for the NDA holder to file an infringement action. A timely suit generally creates a 30-month stay of final ANDA approval under the Hatch-Waxman Act, subject to court action and statutory exceptions. [3]
For US 11,951,111, litigation would likely focus on:
- whether the accused tablet is a bilayer tablet;
- whether each layer falls within the recited excipient ranges;
- whether the product contains 10 mg samidorphan, including an equivalent salt amount;
- whether the product satisfies the dissolution thresholds under the specified USP conditions;
- whether the accused product’s labeling induces once-daily use for schizophrenia or bipolar I disorder;
- whether the claims are anticipated or obvious over earlier olanzapine, samidorphan or fixed-dose formulation disclosures; and
- whether the claims are indefinite because of analytical or compositional boundaries.
The dissolution limitations may be central to both infringement and validity. They are technically specific, but enforceability depends on reproducible testing under the exact buffer, volume, temperature, paddle speed, apparatus and sinker conditions recited in the claims.
How strong is the patent estate for Lybalvi?
The patent estate is strongest against a generic that copies the approved commercial architecture. Its strength is lower against:
- a monolithic tablet rather than a bilayer tablet;
- a capsule or multiparticulate dosage form;
- substantially different filler ratios;
- a formulation without the claimed magnesium stearate concentrations;
- a product with a different samidorphan salt or particle-size distribution;
- a product that fails the claimed rapid-dissolution threshold; or
- a product with labeling that omits the patented treatment method.
The claims have several cumulative limitations. That improves claim definiteness and product targeting, but it creates noninfringement opportunities. A generic need not avoid only one feature if it can alter several formulation parameters while maintaining bioequivalence.
Is there biosimilar risk for olanzapine and samidorphan?
There is no biosimilar pathway for Lybalvi because olanzapine and samidorphan are small-molecule active pharmaceutical ingredients. The relevant competitors are ANDA applicants, not biosimilar sponsors under the Public Health Service Act.
The commercial threat is therefore a generic fixed-dose combination or a therapeutically substitutable olanzapine product. A generic olanzapine monotherapy would not replicate Lybalvi’s samidorphan-based weight-mitigation profile and would not necessarily be a direct substitute.
What licensing deals and commercial relationships matter?
Alkermes developed and commercialized Lybalvi and holds the principal commercial interest in the product. The relevant commercial asset is the combination of olanzapine with samidorphan, not olanzapine itself, which is broadly genericized.
The product’s commercial value depends on:
- protection from olanzapine-associated weight gain;
- physician adoption of the fixed-dose combination;
- payer coverage;
- persistence in schizophrenia treatment;
- approved bipolar I use; and
- the duration of formulation and method-of-use protection.
Lybalvi revenue exposure is concentrated in the period after NCE exclusivity expires but before effective generic entry. A Paragraph IV settlement could preserve revenue by delaying launch while granting an authorized generic or other negotiated entry right.
What generic launch scenarios exist?
| Scenario |
Likely commercial effect |
| No ANDA challenge before NCE expiry |
Continued branded exclusivity until patent or regulatory barriers fall |
| Paragraph IV challenge with no litigation |
Potential approval after regulatory exclusivity, subject to listed patents |
| Paragraph IV litigation and 30-month stay |
Delayed approval while infringement and validity are litigated |
| Formulation design-around |
Possible earlier entry if bioequivalence and labeling requirements are met |
| Authorized generic or settlement |
Controlled entry with reduced price erosion |
| Generic olanzapine only |
Indirect competitive pressure, but not a direct Lybalvi substitute |
| Fixed-dose olanzapine/samidorphan generic |
Direct threat to Lybalvi pricing and volume |
Key Takeaways
- US Patent 11,951,111 protects method-of-treatment use of a coated, immediate-release olanzapine/samidorphan bilayer tablet.
- The claims cover 10 mg samidorphan with selected olanzapine strengths, mainly 5 mg, 10 mg, 15 mg and 20 mg.
- Claim 13 also includes 2.5 mg olanzapine.
- The principal technical limitations are bilayer construction, excipient ranges, samidorphan L-malate, particle size, rapid dissolution and tablet stability.
- The patent does not broadly cover every olanzapine-samidorphan product.
- Lybalvi received FDA approval on June 1, 2021, and its five-year NCE exclusivity nominally runs through June 1, 2026.
- Generic risk will turn on Orange Book listing, Paragraph IV activity, formulation design-arounds and the enforceability of the dissolution limitations.
- Biosimilar risk is not applicable. Any direct competitor would use the ANDA pathway.
- The final patent expiration date requires the complete USPTO continuation-family term record rather than the 2024 grant date alone.
FAQs
Does US Patent 11,951,111 cover olanzapine alone?
No. The claims require a fixed-dose product containing olanzapine and 10 mg samidorphan, administered as a specified bilayer tablet.
Does changing samidorphan L-malate avoid the patent?
Not necessarily. Claims 1, 12 and 13 cover samidorphan or a pharmaceutically acceptable salt in an amount delivering 10 mg samidorphan. Claims 3 and 10-11 are narrower and specifically require samidorphan L-malate.
Can a generic avoid infringement by using a single-layer tablet?
A single-layer product would have a strong noninfringement position against claims requiring a first samidorphan layer and a second olanzapine layer. It would still require separate analysis against other patents in the Lybalvi estate.
Why are the dissolution conditions important?
The claims define infringement partly by release performance under specified USP Apparatus II conditions. A product’s release profile can determine whether it falls within the claims even when its nominal ingredients are similar.
Is FDA approval of a generic Lybalvi product possible after June 1, 2026?
Potentially, but FDA approval would remain subject to applicable Orange Book patents, patent certifications, litigation stays, regulatory exclusivity and the generic product’s bioequivalence and labeling requirements.
References
- U.S. Food and Drug Administration. (2021). FDA approves new drug for treatment-resistant schizophrenia and bipolar I disorder. https://www.fda.gov
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/
- United States Congress. (1984). Drug Price Competition and Patent Term Restoration Act of 1984, 21 U.S.C. § 355(j); 35 U.S.C. § 271(e).
- United States Patent and Trademark Office. (2024). U.S. Patent No. 11,951,111: Patent Center record and patent term information. https://patentcenter.uspto.gov
- Alkermes plc. (2024). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. https://ir.alkermes.com
